title: Myelodysplastic Syndromes: Diagnosis and Treatment.
abstract: In the past few years, new biological insights into the myelodysplastic syndromes (MDS) resulting from molecular genetic analysis have improved pathologic understanding, but treatment advances have not kept pace. More than 40 genes are now known to be recurrently mutated in MDS. However, because most of these genes encode spliceosome components, chromatic remodeling factors, epigenetic pattern modulators, or transcription factors rather than more easily inhibited activated tyrosine kinases, there are as of yet few narrowly targeted therapies available for MDS. Three drugs--azacitidine, decitabine, and lenalidomide--were approved by the US Food and Drug Administration for MDS indications a decade ago, and these agents can improve hematopoiesis, delay disease progression, and improve survival and quality of life for a subset of patients. However, only a few patients with MDS respond to these agents, and their benefit is temporary. The only potentially curative therapy for MDS is allogeneic hematopoietic stem cell transplant, but owing to the advanced age of many patients with MDS and the frequency of serious comorbid conditions, less than 10% of patients currently undergo stem cell transplant. This narrative review summarizes the current understanding of MDS and treatment options for these challenging disorders.
authors.affiliation: Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. Electronic address: David_Steensma@DFCI.harvard.edu.
authors.forename: David P
authors.initials: DP
authors.lastname: Steensma
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D019468:Disease Management; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D033581:Stem Cell Transplantation
chemical_list: D000970:Antineoplastic Agents